Back

Management of atrial fibrillation patients with concomitant need for antiplatelet therapy: Is the dilemma resolved?

3 September 2019 (13:40 - 13:55)
Organised by:
Congress Presentation Part of: Improving outcomes with non-vitamin K antagonist oral anticoagulants (NOACs): Focus on atrial fibrillation patients with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) Stroke Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Peter R Sinnaeve

University Hospitals (UZ) Leuven, Leuven (Belgium)

4 More presentations in this session

Presentation thumbnail
Achievements with NOACs in NVAF to date
Professor M. Gilard (Brest, FR)
Slides Video
Presentation thumbnail
NOACs in atrial fibrillation: Current landscape in clinical practice
Professor N. Danchin (Paris, FR)
Slides Video
Presentation thumbnail
Exploring evidence for long-standing questions
Professor R. Lopes (Durham, US)
Slides Video
Presentation thumbnail
Questions and answers
Professor M. Gilard (Brest, FR) Professor R. Lopes (Durham, US)
Slides

Access the full session

Session thumbnail
Improving outcomes with non-vitamin K antagonist oral anticoagulants (NOACs): Focus on atrial fibrillation patients with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI)

The Event

Event poster

ESC Congress 2019

3 September 2019 13:40 CET
You may be interested in
thumbnail
Webinar
Balancing stroke and bleeding risks in patients with AF and concomitant coronary artery disease, malignancy, chronic kidney disease, or frailty
10 November 2025
thumbnail
Congress Presentation
Impact of clopidogrel metabolizer status on platelet aggregation and association with outcomes in AF patients undergoing PCI
30 August 2025
thumbnail
Congress Presentation
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
2 September 2019
thumbnail
Congress Session
Update on antiarrhythmic therapy
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources